Speculation risks and Equestive collapse

Jim recounts Equestive Therapeutics' FDA setback, stock plunge, and lessons on biotech speculation and regulatory ambiguity.

Play episode from 20:44

Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!